Scaling and Root Planing (SRP): Evidence-Based Periodontal Debridement — Cost, Top Hospitals & Success Rates | MyMedicPlus

Scaling and root planing (SRP), also termed periodontal debridement or cause-related therapy, is the cornerstone non-surgical treatment for Stage I–III periodontitis. It involves systematic removal of supragingival and subgingival microbial biofilm (dental plaque), mineralised deposits (calculus/tartar), and contaminated root surface cementum to disrupt the subgingival microbial ecosystem and facilitate healing of the periodontal tissues.

The scientific rationale for SRP rests on the Socransky microbial complex model: advanced periodontal disease is driven by a consortium of anaerobic Gram-negative organisms — the "red complex" (Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia) — that colonise deep pockets and produce virulence factors (lipopolysaccharide, gingipains, collagenase) responsible for tissue destruction and systemic inflammatory responses. SRP mechanically disrupts and reduces this pathogenic biofilm to levels compatible with periodontal health.

SRP is delivered as Step 2 of the BSP Four-Step Periodontal Care Pathway, following Step 1 oral hygiene instruction and risk factor control. It is performed under local anaesthesia to allow thorough access to the subgingival environment without causing patient discomfort. The procedure is typically completed in two to four sessions, treating one to two quadrants per appointment, allowing approximately one to two weeks of healing between sessions.

The landmark systematic review by Hung and Douglass (2002) confirmed that SRP reduces mean probing pocket depth by 1.0–2.0 mm in moderate pockets (4–6 mm) and by 2.0–3.0 mm in deep pockets (>7 mm), with corresponding clinical attachment level (CAL) gains of 0.5–1.3 mm. Bleeding on probing — the clinical marker of active inflammation — typically reduces by 40–70% within 6–8 weeks of completing SRP, reflecting the shift from a pathogenic to a health-compatible subgingival microbiome.

SRP is indicated across a range of periodontal diagnoses and severity levels. The specific indications are aligned with the 2018 BSP/EFP classification framework:

• Stage I periodontitis — Interdental CAL of 1–2 mm, probing depths of 4 mm or less, with radiographic bone loss in the coronal root third. SRP achieves disease resolution in most cases, often with complete pocket elimination at reassessment.
• Stage II periodontitis — CAL of 3–4 mm, pockets up to 5 mm, bone loss extending to the middle root third. SRP is the primary treatment; the majority of sites respond without requiring surgical intervention.
• Stage III periodontitis (non-surgical phase) — CAL ≥5 mm, deep pockets (>6 mm), furcation Class I–II involvement, and vertical bone defects. SRP is the mandatory first stage of treatment even when surgery is anticipated; sites that respond to SRP may not require surgical access.
• Necrotising periodontal diseases — After acute phase management with gentle debridement and antibiotics, definitive SRP of residual pockets is performed once acute inflammation has resolved.
• Peri-implant mucositis — Reversible peri-implant soft tissue inflammation managed by supramucosal and submucosal debridement, analogous to SRP, using plastic or titanium-compatible curettes to avoid surface scratching.
• Pre-surgical preparation — SRP is always performed and reassessed before any surgical periodontal procedure. Many sites that initially appeared to require surgery achieve adequate clinical improvement following SRP alone, reducing the need for and extent of surgery.
• Supportive periodontal therapy (SPT) — At maintenance recall appointments, subgingival debridement of sites demonstrating bleeding on probing or pocket depths ≥4 mm is performed as a targeted re-treatment, preventing disease recurrence and progression.

SRP is also performed prophylactically in patients with gingivitis as a therapeutic supragingival prophylaxis combined with subgingival scaling, to prevent progression to periodontitis in susceptible individuals.

Eligibility for SRP is determined through clinical examination, periodontal charting, and medical history review:

• Periodontal charting threshold — SRP is indicated in patients with any BPE code 3 or 4 sextant (probing depths of 4 mm or more at multiple sites). Full six-point charting confirms the distribution and severity of disease, identifying which sextants and individual sites require subgingival instrumentation.
• Oral hygiene prerequisite — Patients are required to demonstrate improved oral hygiene through Step 1 instruction before commencing SRP. Individuals with Full Mouth Plaque Scores (FMPS) above 30% are unlikely to maintain SRP gains, as rapid biofilm re-colonisation negates the therapeutic benefit of subgingival debridement.
• Medical fitness — The vast majority of patients are medically suitable for SRP under local anaesthesia. Anticoagulated patients (warfarin INR ≤3.5 or direct oral anticoagulants) do not require medication changes. Antiplatelet therapy need not be interrupted. Patients with known allergy to local anaesthetic agents (amide type) require alternative agents or specialist referral.
• Diabetes mellitus — SRP is actively indicated and clinically beneficial in all diabetic patients with periodontitis. HbA1c levels do not preclude treatment; indeed, periodontal therapy contributes to glycaemic improvement. Morning appointments are preferred to avoid hypoglycaemia risk in insulin-dependent patients.
• Pregnancy — SRP is safe and clinically recommended at any trimester for patients with Stage I–III periodontitis. Periodontitis in pregnancy is associated with preterm delivery and low birth weight; treatment is therefore both safe and medically important.
• Bisphosphonates and antiresorptive medications — SRP is safe in patients on oral or intravenous bisphosphonates and denosumab. Surgical periodontal therapy (flap procedures) requires individualised MRONJ risk assessment, but non-surgical SRP is not contraindicated.

SRP employs two principal categories of instruments, often used in combination, each with distinct advantages:

• Ultrasonic scalers — piezoelectric type: A ceramic crystal stack converts electrical energy into linear oscillating tip movement at 25,000–45,000 Hz. The tip moves in a push-pull linear direction, ideal for precision root surface instrumentation and narrow pocket access. Water coolant provides lavage, cavitation, and acoustic microstreaming that disrupts biofilm even on surfaces not directly contacted by the tip. Examples: Satelec P5 Newtron, EMS Piezon.
• Ultrasonic scalers — magnetostrictive type: Metal stack inserts oscillate in an elliptical pattern at 18,000–45,000 Hz, allowing all four sides of the tip to be active. The water coolant also generates cavitation and acoustic streaming, enhancing biofilm disruption. Examples: Cavitron (Dentsply), Satalec.
• Hand instruments — Gracey curettes: Area-specific instruments designed by Clayton Gracey in the 1930s and modified since. The most commonly used set includes: 5/6 for anterior teeth, 7/8 for posterior buccal/lingual surfaces, 11/12 for mesial surfaces of posterior teeth, and 13/14 for distal surfaces of posterior teeth. After-Five and Mini-Five extensions allow deeper pocket access (5 mm or more). The lower shank angulation of Gracey curettes ensures the cutting edge automatically adapts to the correct root surface angle, reducing technique sensitivity compared to universal curettes.
• Full-mouth disinfection (FMD) protocol: Quadrants completed within 24–48 hours, combined with subgingival irrigation using 1% chlorhexidine gel, tongue brushing with 1% chlorhexidine gel, and 0.2% chlorhexidine mouthwash twice daily for two weeks. First described by Quirynen et al. (1995), FMD aims to prevent re-infection of treated sites from untreated pockets in the same oral cavity.
• Adjunctive systemic antibiotics: For generalised Stage III–IV Grade C disease, amoxicillin 500 mg plus metronidazole 400 mg three times daily for 7 days concurrent with or immediately after completing full-mouth SRP. In penicillin-allergic patients, metronidazole 400 mg plus azithromycin 500 mg daily for 5 days is an alternative.
• Adjunctive local antimicrobials: Placed in residual pockets ≥5 mm at the 8–12 week reassessment visit: doxycycline hyclate 10% gel (Atridox), minocycline microspheres (Arestin), or chlorhexidine gluconate 2.5 mg chip (PerioChip).

SRP produces robust and well-documented clinical improvements across a range of validated outcome measures:

• Probing pocket depth (PPD) reduction — Systematic reviews consistently report mean PPD reductions of 1.0–2.0 mm in moderate pockets (4–6 mm) and 2.0–3.0 mm in deep pockets (>7 mm). Deep pockets demonstrate greater absolute depth reduction because there is more pathological pocket to resolve.
• Clinical attachment level (CAL) gain — Mean CAL gain of 0.5–1.3 mm is achieved by SRP. Deep sites (>6 mm) gain more attachment than shallow sites (4–5 mm), which may experience slight recession as the dominant healing mechanism rather than CAL gain.
• Bleeding on probing (BOP) reduction — Bleeding on probing is the most sensitive clinical marker of active gingival inflammation. SRP typically reduces BOP by 40–70% within 6–8 weeks, reflecting the shift from a pathogenic to a health-compatible subgingival microbiome and the resolution of ulcerated sulcular epithelium.
• Microbiome rebalancing — SRP disrupts the "red complex" and "orange complex" pathogenic biofilm. Quantitative PCR studies demonstrate significant reductions in Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia counts persisting at 3 and 6 months post-SRP, with corresponding increases in health-associated Streptococcus and Actinomyces species.
• Systemic inflammatory marker reduction — Successful SRP reduces systemic levels of CRP, IL-6, and fibrinogen, potentially reducing cardiovascular and metabolic disease risk in patients with severe periodontitis.
• Glycaemic improvement — In patients with type 2 diabetes, SRP alone reduces HbA1c by approximately 0.4–0.6% at 3–6 months, independent of changes in antidiabetic medication.
• Patient-reported outcomes — Resolution of bleeding gums, halitosis, and gum tenderness significantly improve patients' oral health-related quality of life as measured by OHIP-14 questionnaires, often from the first SRP session onward.

SRP is a minimally invasive procedure with an excellent safety profile, but patients should be aware of the following possible side-effects and complications:

• Dentine hypersensitivity — The most common side-effect, affecting approximately 60–90% of treated patients to some degree. SRP removes cementum and may expose dentinal tubules at the cemento-enamel junction, causing sharp, brief pain in response to cold air, cold water, acidic foods, or touch. Management options include desensitising toothpastes containing 5% potassium nitrate, 0.454% stannous fluoride, or 8% arginine; in-office fluoride varnish (5% NaF); or dentine bonding agents for severe refractory cases. Most sensitivity resolves within 4–8 weeks.
• Gingival recession and interdental spacing — Elimination of inflammatory oedema following SRP often reveals underlying gingival recession and results in visible interdental black triangles (open embrasure spaces). This is an expected and desired outcome of reduced gingival inflammation — not a complication — but patients must be informed pre-operatively to avoid distress at appearance changes.
• Post-procedural discomfort — Mild soreness and sensitivity lasting 24–72 hours are common. Simple analgesia (ibuprofen 400 mg three times daily with food, or paracetamol 1 g four times daily) provides effective relief. A soft diet is advised for 24–48 hours after each session.
• Transient bacteraemia — Brief bacteraemia is an expected consequence of all subgingival debridement. UK NICE guideline CG64 does not recommend routine antibiotic prophylaxis for patients with structural heart disease undergoing dental procedures; however, individual clinical assessment for patients at highest endocarditis risk (prosthetic valves, previous infective endocarditis) remains appropriate.
• Incomplete calculus removal — In very deep pockets (>7 mm), furcation-involved teeth, or narrow root concavities, complete removal of all subgingival calculus by non-surgical means alone is physically impossible. This is a primary rationale for surgical access therapy in pockets persisting after SRP reassessment.
• Cementum removal — Aggressive SRP can remove excessive cementum from root surfaces, potentially weakening the root and exposing dentinal tubules. Modern powered scalers with controlled settings and light-touch hand instrumentation minimise this risk.

The reassessment phase following completion of SRP is critical for evaluating treatment outcomes and planning subsequent management. The 2020 EFP S3-level Clinical Practice Guideline specifies a structured follow-up pathway:

• Reassessment appointment timing — Full-mouth periodontal re-charting is performed at 8–12 weeks after the final SRP appointment. This interval allows complete resolution of acute gingival inflammation and oedema, providing accurate probing depth measurements unconfounded by tissue swelling. Reassessment performed too early (<6 weeks) may underestimate pockets due to residual inflammation masking clinical depths.
• Clinical outcomes assessed — Re-charting records six-point probing depths, bleeding on probing, suppuration, furcation involvement, and tooth mobility at all sites. Full Mouth Bleeding Score (FMBS) reduction of >50% from baseline indicates an adequate treatment response. Sites retaining pocket depths ≥6 mm with ongoing BOP represent active disease and candidates for surgical intervention or specialist referral.
• Entry into supportive periodontal therapy (SPT) — After reassessment, all patients with Stage II–IV periodontitis enter lifelong SPT. Recall intervals are risk-stratified: 3 months for high-risk patients (active smokers, poorly controlled diabetes, persistent deep pockets); 3–4 months for moderate risk; and 6 months for low-risk patients with an excellent treatment response and good oral hygiene.
• SPT subgingival debridement — At each SPT visit, sites demonstrating bleeding on probing or pockets ≥4 mm receive targeted subgingival debridement — effectively re-treatment SRP at relapsing sites — preventing disease recurrence and progressive bone loss.
• Radiographic reassessment — Vertical bitewing radiographs at 12–24 month intervals during SPT detect interproximal bone level changes indicating disease progression or stability.

Long-term studies demonstrate that patients who comply with regular SPT after SRP maintain substantially stable probing depths and CAL for 10–20 years, with low rates of tooth loss. Non-compliant patients experience progressive attachment loss and higher tooth extraction rates within 3–5 years of completing active treatment.

The cost of SRP depends on the number of quadrants requiring treatment, severity of disease, anaesthetic requirements, adjunctive therapies, and geographic location. Key considerations include:

• Number of quadrants treated — Mild disease involving only one or two quadrants is significantly less costly than full-mouth SRP across all four quadrants with multiple sessions. Most patients with moderate-to-severe periodontitis require full-mouth treatment.
• NHS costs (UK) — SRP provided by a general dental practitioner within the NHS is included under Band 2 treatment (approximately £65.20 at 2025/26 charge rates), regardless of the number of quadrants or appointments required. This represents outstanding value but access to NHS periodontal specialists may involve waiting lists.
• Private costs (UK) — Private SRP by a general dentist ranges from £150–£350 per quadrant. Specialist periodontist fees range from £200–£500 per quadrant. A full-mouth private SRP course therefore typically costs £600–£2,000, depending on severity and provider.
• Adjunctive antimicrobial costs — Local antimicrobial agents (Atridox, Arestin, PerioChip) add £50–£200 per pocket treatment site. Systemic antibiotic courses (amoxicillin plus metronidazole for 7 days) add approximately £10–£20 for the medications.
• Dental tourism savings — Full-mouth SRP in India, Hungary, Poland, or Thailand costs approximately $100–$350 USD, representing savings of 70–85% compared to UK private fees. These destinations offer JCI-accredited dental facilities with equivalent instrumentation and clinical protocols.
• Long-term cost-effectiveness — Investment in SRP and ongoing SPT is substantially more cost-effective over 10–20 years than dental implants or bridges required after tooth loss from undertreated periodontitis. A single implant in the UK costs £2,000–£4,000; preventing one tooth loss through periodontal treatment represents significant savings.

SRP is the gold-standard non-surgical periodontal treatment, with the strongest evidence base of any periodontal intervention. The following alternatives or adjuncts are relevant in specific clinical contexts:

• Supragingival prophylaxis alone — For gingivitis without attachment loss, professional supragingival cleaning combined with home care instruction may be sufficient. However, for any established periodontitis with true pocketing and attachment loss, supragingival cleaning alone is insufficient, as it does not access the subgingival biofilm causing disease progression.
• Full-mouth disinfection (FMD) — An alternative scheduling approach completing all quadrants within 24 hours with adjunctive chlorhexidine across all oral surfaces. Meta-analyses show a marginal additional benefit of 0.2–0.4 mm additional pocket depth reduction compared to conventional SRP, but no clinically superior attachment gain. FMD remains a legitimate approach for selected cases.
• Laser-assisted debridement — Er:YAG lasers can ablate calculus and contaminated root surface cementum, and Nd:YAG lasers have been used for soft tissue treatment. Systematic reviews conclude that laser treatment as an adjunct or alternative to SRP provides no significant additional benefit, and no laser system is currently endorsed as a SRP replacement by the EFP or AAP.
• Air polishing with glycine powder — Subgingival glycine powder air polishing (e.g., Perio-Flow, EMS) effectively removes subgingival biofilm from pockets up to 9 mm deep and has emerged as a useful adjunct or alternative for biofilm removal at SPT visits, particularly around implants. It does not remove calculus and requires conventional instrumentation for calculus-containing sites.
• Host modulation therapy — Sub-antimicrobial dose doxycycline (Periostat 20 mg twice daily) is FDA-approved as an adjunct to SRP, inhibiting collagen-destructive matrix metalloproteinases without antibiotic selection pressure.
• Surgical therapy — For pockets ≥6 mm persisting after SRP, surgical access therapy (flap procedures) allows complete visualisation and instrumentation of the root surface, achieving additional pocket depth reduction of 0.6–1.0 mm compared to SRP alone.